Correspondence 0001493152-24-030489 from Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc.
Date: Aug. 7, 2024 · CIK: 0001642380 · Accession: 0001493152-24-030489
AI Filing Summary & Sentiment
File numbers found in text: 333-281159
Letter
Oncocyte Corporation
Cushing
Irvine, California 92618
(949) 409-7600
August 7, 2024
SUBMITTED VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
F Street, N.E.
Washington, DC 20549
Re: Oncocyte Corporation Acceleration Request
Registration Statement on Form S-3
Filed August 1, 2024
File No. 333-281159
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Oncocyte Corporation (the “Company”), hereby respectfully requests that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and declare the Registration Statement effective as of 5:00 P.M., Eastern Time, on August 7, 2024, or as soon thereafter as is practicable, or at such other time as the Company or its counsel may orally request by telephone.
Should the Securities and Exchange Commission have any questions regarding this acceleration request, please do not hesitate to contact Christopher P. McCaskill, an attorney with the Company’s outside legal counsel, Stradling Yocca Carlson & Rauth LLP, via telephone at (949) 725-4028 or via email at pmccaskill@stradlinglaw.com. We respectfully request that you contact Mr. McCaskill via telephone as soon as the above-referenced Registration Statement has been declared effective.
Sincerely,
ONCOCYTE
CORPORATION
Show Raw Text
CORRESP
1
filename1.htm
Oncocyte
Corporation
15
Cushing
Irvine,
California 92618
(949)
409-7600
August
7, 2024
SUBMITTED
VIA EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporate Finance
100
F Street, N.E.
Washington,
DC 20549
Re:
Oncocyte
Corporation Acceleration Request
Registration
Statement on Form S-3
Filed
August 1, 2024
File
No. 333-281159
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Oncocyte Corporation (the “Company”),
hereby respectfully requests that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration
Statement on Form S-3 (the “Registration Statement”), and declare the Registration Statement effective as of 5:00 P.M., Eastern
Time, on August 7, 2024, or as soon thereafter as is practicable, or at such other time as the Company or its counsel may orally request
by telephone.
Should
the Securities and Exchange Commission have any questions regarding this acceleration request, please do not hesitate to contact Christopher
P. McCaskill, an attorney with the Company’s outside legal counsel, Stradling Yocca Carlson & Rauth LLP, via telephone at (949)
725-4028 or via email at pmccaskill@stradlinglaw.com. We respectfully request that you contact Mr. McCaskill via telephone as soon as
the above-referenced Registration Statement has been declared effective.
Sincerely,
ONCOCYTE
CORPORATION
/s/
Joshua Riggs
Joshua
Riggs
President
and Chief Executive Officer
cc:
Oncocyte
Corporation
Andrea
James, Chief Financial Officer
Stradling
Yocca Carlson & Rauth LLP
Christopher
P. McCaskill, Esq.